Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
Endometrial cancer is one of the most common gynaecological cancers in both the United States and the Russian Federation, and the rate continues to rise. Although early-stage endometrial cancer is associated with a favourable 5-year survival rate (96%), this rate in patients with distant metastases...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2023-01-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/738 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696900009164800 |
|---|---|
| author | K. V. Menshikov A. V. Sultanbaev Sh. I. Musin I. A. Menshikova N. I. Sultanbaeva A. A. Izmailov A. A. Fatikhova D. O. Lipatov G. A. Serebrennikov |
| author_facet | K. V. Menshikov A. V. Sultanbaev Sh. I. Musin I. A. Menshikova N. I. Sultanbaeva A. A. Izmailov A. A. Fatikhova D. O. Lipatov G. A. Serebrennikov |
| author_sort | K. V. Menshikov |
| collection | DOAJ |
| description | Endometrial cancer is one of the most common gynaecological cancers in both the United States and the Russian Federation, and the rate continues to rise. Although early-stage endometrial cancer is associated with a favourable 5-year survival rate (96%), this rate in patients with distant metastases accounts for only 18%. A combination of paclitaxel and carboplatin is standard first-line therapy for advanced, recurrent and metastatic endometrial carcinoma. Pembrolizumab, a monoclonal antibody targeting the programmed death-1 receptor, is approved for therapy of metastatic solid tumors with high microsatellite instability that have progressed aft er previous therapy and have no alternative treatment options. Lenvatinib is an oral multikinase inhibitor that blocks vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor alpha, RET and KIT. Phase II and III studies (KEYNOTE-146/ Study111 and KEYNOTE-775) on the combination of lenvatinib and pembrolizumab in advanced endometrial carcinoma, irrespective of MMR and MSI status, have shown new potential for the treatment of this pathology. Th e results obtained, including progression-free and overall survival, allow the combination of lenvatinib and pembrolizumab to be considered a new standard for the treatment of this pathology. |
| format | Article |
| id | doaj-art-7fae7ffaa58d4d01ae2f639ddb483807 |
| institution | DOAJ |
| issn | 2076-3093 2307-0501 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Bashkir State Medical University |
| record_format | Article |
| series | Креативная хирургия и онкология |
| spelling | doaj-art-7fae7ffaa58d4d01ae2f639ddb4838072025-08-20T03:19:20ZengBashkir State Medical UniversityКреативная хирургия и онкология2076-30932307-05012023-01-0112430931910.24060/2076-3093-2022-12-4-309-319503Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinomaK. V. Menshikov0A. V. Sultanbaev1Sh. I. Musin2I. A. Menshikova3N. I. Sultanbaeva4A. A. Izmailov5A. A. Fatikhova6D. O. Lipatov7G. A. Serebrennikov8Republican Clinical Oncology Dispensary; Bashkir State Medical UniversityRepublican Clinical Oncology DispensaryRepublican Clinical Oncology DispensaryBashkir State Medical UniversityRepublican Clinical Oncology DispensaryRepublican Clinical Oncology Dispensary; Bashkir State Medical UniversityRepublican Clinical Oncology DispensaryBashkir State Medical UniversityRepublican Clinical Oncology DispensaryEndometrial cancer is one of the most common gynaecological cancers in both the United States and the Russian Federation, and the rate continues to rise. Although early-stage endometrial cancer is associated with a favourable 5-year survival rate (96%), this rate in patients with distant metastases accounts for only 18%. A combination of paclitaxel and carboplatin is standard first-line therapy for advanced, recurrent and metastatic endometrial carcinoma. Pembrolizumab, a monoclonal antibody targeting the programmed death-1 receptor, is approved for therapy of metastatic solid tumors with high microsatellite instability that have progressed aft er previous therapy and have no alternative treatment options. Lenvatinib is an oral multikinase inhibitor that blocks vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor alpha, RET and KIT. Phase II and III studies (KEYNOTE-146/ Study111 and KEYNOTE-775) on the combination of lenvatinib and pembrolizumab in advanced endometrial carcinoma, irrespective of MMR and MSI status, have shown new potential for the treatment of this pathology. Th e results obtained, including progression-free and overall survival, allow the combination of lenvatinib and pembrolizumab to be considered a new standard for the treatment of this pathology.https://www.surgonco.ru/jour/article/view/738endometrial carcinomamicrosatellite instabilityimmunotherapychemotherapytyrosine kinase inhibitorslenvatinibpembrolizumab |
| spellingShingle | K. V. Menshikov A. V. Sultanbaev Sh. I. Musin I. A. Menshikova N. I. Sultanbaeva A. A. Izmailov A. A. Fatikhova D. O. Lipatov G. A. Serebrennikov Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma Креативная хирургия и онкология endometrial carcinoma microsatellite instability immunotherapy chemotherapy tyrosine kinase inhibitors lenvatinib pembrolizumab |
| title | Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma |
| title_full | Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma |
| title_fullStr | Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma |
| title_full_unstemmed | Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma |
| title_short | Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma |
| title_sort | possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma |
| topic | endometrial carcinoma microsatellite instability immunotherapy chemotherapy tyrosine kinase inhibitors lenvatinib pembrolizumab |
| url | https://www.surgonco.ru/jour/article/view/738 |
| work_keys_str_mv | AT kvmenshikov possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT avsultanbaev possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT shimusin possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT iamenshikova possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT nisultanbaeva possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT aaizmailov possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT aafatikhova possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT dolipatov possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma AT gaserebrennikov possibleapplicationsforcombinedlenvatinibandpembrolizumabinadvancedendometrialcarcinoma |